Latest news with #NeuPath
Business Wire
2 days ago
- Business
- Business Wire
NEUPATH HEALTH TO REPORT Q2 RESULTS AND HOST INVESTOR WEBINAR
TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), ('NeuPath' or the 'Company'), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced that it will release its financial results for the second quarter of 2025 before market open on Thursday, August 14, 2025. Investors and stakeholders are invited to join a live webinar with Joe Walewicz, Chief Executive Officer of NeuPath, for a detailed presentation and discussion of the Company's results, operations and strategic outlook. Event: Presentation and Q&A Webinar with NeuPath Health Inc. (NPTH) Host: Martin Gagel, Radius Research Presentation Date & Time: Webcast Registration Link: Market Radius Research gives individual investors access to in-depth CEO interviews with deep-dive institutional level discussion and Q&A. Market Radius is hosted by Martin Gagel, former top-ranked technology analyst. By registering for this webinar, you agree to receive email communications from Market Radius Capital, Inc. and from the presenting company (with unsubscribe). Your email will not be further shared. Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice and may own shares in mentioned companies and are compensated by the Company for these services. Content is for information purposes only and is not advice or recommendations and may include incomplete or incorrect information. Investing entails a high degree of risk. This is a production of Market Radius Capital, Inc. About NeuPath Health Inc. NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit Forward Looking Information: This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company's expectation of continued operational improvements in 2025 and the execution of the Company's growth opportunities are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company's Annual Information Form dated March 26, 2025 filed on SEDAR+ under the Company's profile at Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty. NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
National Post
2 days ago
- Business
- National Post
NEUPATH HEALTH TO REPORT Q2 RESULTS AND HOST INVESTOR WEBINAR
Article content NeuPath to report Q2 2025 results on August 14 th before markets open Article content TORONTO — NeuPath Health Inc. (TSXV:NPTH), ('NeuPath' or the 'Company'), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced that it will release its financial results for the second quarter of 2025 before market open on Thursday, August 14, 2025. Investors and stakeholders are invited to join a live webinar with Joe Walewicz, Chief Executive Officer of NeuPath, for a detailed presentation and discussion of the Company's results, operations and strategic outlook. Article content Article content Event: Article content Presentation and Q&A Webinar with NeuPath Health Inc. (NPTH) Article content Article content Host: Article content Martin Gagel, Radius Research Article content Article content Presentation Date & Time: Article content Thursday, August 21, 2025 at 10:00 AM ET / 7:00 AM PT Article content Article content Webcast Registration Link: Article content Market Radius Research gives individual investors access to in-depth CEO interviews with deep-dive institutional level discussion and Q&A. Market Radius is hosted by Martin Gagel, former top-ranked technology analyst. By registering for this webinar, you agree to receive email communications from Market Radius Capital, Inc. and from the presenting company (with unsubscribe). Your email will not be further shared. Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice and may own shares in mentioned companies and are compensated by the Company for these services. Content is for information purposes only and is not advice or recommendations and may include incomplete or incorrect information. Investing entails a high degree of risk. This is a production of Market Radius Capital, Inc. Article content About NeuPath Health Inc. Article content NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit Article content Forward Looking Information: Article content This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company's expectation of continued operational improvements in 2025 and the execution of the Company's growth opportunities are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company's Annual Information Form dated March 26, 2025 filed on SEDAR+ under the Company's profile at Article content Article content . Article content Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty. Article content Article content Article content Article content Article content Contacts Article content For further information, please contact: Article content Article content Article content
Business Wire
12-06-2025
- Business
- Business Wire
NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), ('NeuPath' or the 'Company'), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the 'Meeting') held on June 11, 2025 and the grant of stock options ('Options') and restricted share units ('RSUs'). All figures are in Canadian dollars, unless otherwise noted. The results of the director elections were as follows: The shareholders of the Company also voted: (i) to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Company for the ensuing year, (ii) to approve the Company's amended and restated stock option plan in the form attached as Schedule 'A' to the management information circular dated April 22, 2025 prepared in connection with the Meeting (the 'Stock Option Plan'), and (iii) to approve the Company's amended and restated restricted share unit plan in the form attached as Schedule 'B' to the management information circular dated April 22, 2025 prepared in connection with the Meeting (the 'RSU Plan'). Amendments to the RSU Plan At the Meeting, the Company proposed the adoption of the RSU Plan which was amended to increase the maximum number of common shares of the Company ('Common Shares') issuable thereunder from 3,000,000 Common Shares to 5,000,000 Common Shares. At the Meeting, 99.38% shareholder votes cast were in favour of adopting the RSU Plan. Issuance of Stock Options and Restricted Share Units On June 12, 2025, NeuPath granted an aggregate of 150,000 Options to non-executive directors of the Company at an exercise price of $0.26 per share, with an expiry date of June 12, 2032. The Options are subject to time-based vesting and will fully vest on June 12, 2026. The terms of the Options granted are in accordance with the Stock Option Plan. In addition, on June 12, 2025, the Company granted an aggregate of 60,000 RSUs to the same non-executive directors of the Company. The RSUs are subject to time-based vesting in accordance with the policies of the TSX Venture Exchange. RSUs granted will fully vest on June 12, 2026. The terms of the RSUs granted are in accordance with the RSU Plan. About NeuPath NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit
Yahoo
12-06-2025
- Business
- Yahoo
NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
TORONTO, June 12, 2025--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), ("NeuPath" or the "Company"), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on June 11, 2025 and the grant of stock options ("Options") and restricted share units ("RSUs"). All figures are in Canadian dollars, unless otherwise noted. The results of the director elections were as follows: Name Votes in Favour % Votes in Favour Votes Withheld % Votes Withheld Jolyon Burton 15,780,716 99.99% 1,000 0.01% Daniel Chicoine 15,780,716 99.99% 1,000 0.01% Sasha Cucuz 15,775,716 99.96% 6,000 0.04% Dan Legault 15,780,716 99.99% 1,000 0.01% Joseph Walewicz 15,780,716 99.99% 1,000 0.01% The shareholders of the Company also voted: (i) to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Company for the ensuing year, (ii) to approve the Company's amended and restated stock option plan in the form attached as Schedule "A" to the management information circular dated April 22, 2025 prepared in connection with the Meeting (the "Stock Option Plan"), and (iii) to approve the Company's amended and restated restricted share unit plan in the form attached as Schedule "B" to the management information circular dated April 22, 2025 prepared in connection with the Meeting (the "RSU Plan"). Amendments to the RSU Plan At the Meeting, the Company proposed the adoption of the RSU Plan which was amended to increase the maximum number of common shares of the Company ("Common Shares") issuable thereunder from 3,000,000 Common Shares to 5,000,000 Common Shares. At the Meeting, 99.38% shareholder votes cast were in favour of adopting the RSU Plan. Issuance of Stock Options and Restricted Share Units On June 12, 2025, NeuPath granted an aggregate of 150,000 Options to non-executive directors of the Company at an exercise price of $0.26 per share, with an expiry date of June 12, 2032. The Options are subject to time-based vesting and will fully vest on June 12, 2026. The terms of the Options granted are in accordance with the Stock Option Plan. In addition, on June 12, 2025, the Company granted an aggregate of 60,000 RSUs to the same non-executive directors of the Company. The RSUs are subject to time-based vesting in accordance with the policies of the TSX Venture Exchange. RSUs granted will fully vest on June 12, 2026. The terms of the RSUs granted are in accordance with the RSU Plan. About NeuPath NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. View source version on Contacts For more information, please contact: Jeff ZygourasChief Financial Officerinfo@ (905) 858-1368 Sign in to access your portfolio
Associated Press
15-05-2025
- Business
- Associated Press
NEUPATH HEALTH REPORTS FIRST QUARTER 2025 RESULTS
TORONTO--(BUSINESS WIRE)--May 15, 2025-- NeuPath Health Inc. (TSXV:NPTH), ('NeuPath' or the 'Company'), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three months March 31, 2025 and the grant of stock options ('Options') and restricted share units ('RSUs'). All figures are in Canadian dollars, unless otherwise noted. 'Strong organic growth in Alberta and Ontario, combined with careful attention to our operations and our clinic footprint, continues to deliver improved operating results,' said Joe Walewicz, NeuPath's Chief Executive Officer. 'We expect continued growth and improved results in 2025, as we continue to evaluate multiple inorganic growth opportunities to better serve patients, with more services, in more communities.' Financial and Operational Highlights Q1 2025 Financial Results Gross margin % was 18.8% for the three months ended March 31, 2025 compared to 18.5% for the three months ended March 31, 2024. The increase in gross margin was primarily driven by higher revenues from fluoroscopy and positive adjustments to physician reimbursement rates compared to the comparative quarter (see Non-IFRS Financial Measures - Gross Margin and Gross Margin %). Adjusted EBITDA was $1.3 million for the three months ended March 31, 2025 compared to $0.9 million for the three months March 31, 2024. For more information see Note 5, Long-Term Debt in the Company's Condensed Consolidated Interim Financial Statements for the three months ended March 31, 2025, and Note 6, Long-Term Debt in the Company's Condensed Consolidated Interim Financial Statements for the three months ended March 31, 2024. Issuance of Stock Options and Restricted Share Units The Company has approved the grant of 375,000 Options to an officer of the Company, to be issued on May 21, 2025, at an exercise price equal to the closing price on the last trading day immediately preceding the grant date, and with an expiry date of May 21, 2032. The terms of the Options granted are in accordance with the Company's Amended and Restated Stock Option Plan. The Options are subject to time-based vesting and will vest annually in equal instalments on each anniversary date from the date of grant for 4 years. In addition, the Company approved the grant of 375,000 RSUs to the same officer of the Company, to be issued on May 21, 2025. The RSUs are subject to time-based vesting and will fully vest on May 21, 2029. One quarter of the RSUs granted will vest annually on each anniversary date from the date of grant for 4 years. The terms of the RSUs granted are in accordance with the Company's Amended and Restated Restricted Share Unit Plan. Non-IFRS Financial and Other Measures The Company discloses non-IFRS measures (such as EBITDA, Adjusted EBITDA, and gross margin) and non-IFRS ratios (such as gross margin %) that do not have standardized meanings prescribed by International Financial Reporting Standards ('IFRS'). The Company believes that shareholders, investment analysts and other readers find such measures helpful in understanding the Company's financial performance. Non-IFRS financial measures and other measures do not have any standardized meaning prescribed by IFRS and may not have been calculated in the same way as similarly named financial measures presented by other reporting issuers and therefore unlikely to be comparable to similar measures presented by other companies. Furthermore, these non-IFRS measures and other measures should not be considered in isolation or as a substitute for measures of performance or cash flows as prepared in accordance with IFRS. These measures should be considered as supplemental in nature and not as a substitute for related financial information prepared in accordance with IFRS. The following table provides a reconciliation of net and comprehensive loss to EBITDA and Adjusted EBITDA: The following table provides a reconciliation of total revenue to gross margin: For further details on the results, please refer to NeuPath's Management, Discussion and Analysis and Condensed Consolidated Interim Financial Statements for the three months ended March 31, 2025, which are available on the Company's website ( ) and under the Company's profile on SEDAR+ ( ). About NeuPath NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit Forward-Looking Statements This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company's expectation of continued operational improvements in 2025 and the execution of the Company's growth opportunities are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company's Annual Information Form dated March 26, 2025 filed on SEDAR + under the Company's profile Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent source version on CONTACT: For more information, please contact:Jeff Zygouras Chief Financial Officer [email protected] (905) 858-1368 KEYWORD: NORTH AMERICA CANADA INDUSTRY KEYWORD: HEALTH HOSPITALS PHYSICAL THERAPY OTHER HEALTH MANAGED CARE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: NeuPath Health Inc. Copyright Business Wire 2025. PUB: 05/15/2025 07:30 AM/DISC: 05/15/2025 07:29 AM
